AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy
The European Commission has cleared AstraZeneca and Merck & Co’s Lynparza as an adjuvant or neoadjuvant treatment for breast cancer, extending its lead over would-be rivals in the PARP inhibitor class. The new approval is for use in patients with BRCA-mutated, HER2-negative early-stage breast cancer who have already been treated with chemotherapy – either before …
AZ, Merck get EU nod for Lynparza as adjuvant breast cancer therapy Read More »